Artificial Intelligence
OpGen Provides Update on Curetis Group Company Ares Genetics’ Collaboration with BGI Group to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe
- BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCR
- Ares Genetics to launch next-generation sequencing testing service for infection control and monitoring of 2019-nCoV evolution using BGI Group reagents
- Ares Genetics, Curetis Group and BGI Group to collaborate in the distribution of next-generation sequencing and PCR testing kits for 2019-nCoV
GAITHERSBURG, Md., Jan. 30, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH (“Curetis”), the other party to the planned business combination with OpGen. Today, Curetis announced that Ares Genetics GmbH, a Curetis Group company, and the Chinese genomics company BGI Group will collaborate in making molecular testing for the new coronavirus 2019-nCoV available in Europe.
2019-nCoV is a new coronavirus variant that has not been previously identified in humans but is responsible for the outbreak originating in the Chinese city of Wuhan and rapidly spreading globally with first cases identified and confirmed in Europe already. In response to this situation, and immediately after the occurrence of unexplained pneumonia in Wuhan on December 31, 2019, BGI was first to sequence the genome of the new 2019-nCoV virus and successfully developed a Real-Time (RT) Fluorescent PCR (polymerase chain reaction) kit for detecting 2019-nCoV, which can provide results in a few hours and has already obtained approval by the Chinese National Medical Products Administration.
In addition to the rapid detection kit based on RT-PCR technology, the DNBSEQ-T7 sequencing platform developed by BGI Group’s instrument and reagent subsidiary, MGI, passed the emergency approval procedure of the National Medical Products Administration, becoming the first officially approved testing products in China for surveillance, discovery and identification of unknown infectious diseases.
In Europe, BGI and MGI will work with their long-term strategic partner Ares Genetics to make its 2019-nCoV testing portfolio available to public health institutions and hospitals for outbreak monitoring, infection control, and epidemiology. Ares Genetics expects to provide next-generation sequencing services for 2019-nCoV out of its NGS laboratory in Vienna, Austria, for infection control and tracking of pathogen evolution from February 2020 onwards based on MGI’s DNBSEQ sequencing platform. Further, Ares Genetics and the Curetis Group will support BGI Group in the distribution of its PCR and NGS reagent kits to molecular testing laboratories in Europe that have the capability for 2019-nCoV testing with reagent kits initially being marketed for research use only prior to regulatory approval in Europe.
Ares Genetics is a digital diagnostics company utilizing artificial intelligence-powered molecular diagnostics to advance the field of infectious disease testing. Ares Genetics recently launched ARESupa – Universal Pathogenome Assay for the broad identification of bacterial pathogens and the accurate prediction of antibiotic susceptibility. The ARESupa test is based on the sequencing of bacterial DNA, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. The first generation of ARESupa is currently offered for non-diagnostic applications in epidemiology, infection control, and outbreak analysis for customers in the public health sector and the pharmaceutical industry. A laboratory-developed test (LDT) for human diagnostic use is under development.
“This collaboration highlights the importance of rapid testing technologies in tracking the evolution of and containing global outbreaks. We congratulate Curetis on their collaboration and commend them and BGI Group for their swift action to assist in the surveillance and identification of yet another infectious disease with cases across the globe,” said Evan Jones, Chairman & CEO of OpGen.
OpGen and Curetis entered into a definitive agreement to combine businesses on September 4, 2019. The closing of the transaction under such definitive agreement has not yet occurred and is subject to a number of significant closing conditions, including receipt of approval from the stockholders of OpGen, Inc. and the shareholders of Curetis, N.V. Until the closing occurs, each of OpGen and Curetis are operating as stand-alone businesses.
About OpGen
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Our proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections.
Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas® molecular diagnostics and Acuitas Lighthouse® informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. Currently we offer our Acuitas AMR Gene Panel tests for research use only. For more information, please visit www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.
Forward-Looking Statements
This press release includes statements relating to the proposed business combination transaction between OpGen and Curetis and a planned collaboration between Curetis Group company, Ares Genetics, and BGI Group for next-generation sequencing and PCR-based coronavirus testing in Europe. These statements and other statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully and timely seek approval of, and obtain approval of our stockholders for the transaction, satisfy the closing conditions under the implementation agreement between OpGen and Curetis, successfully combine the businesses of OpGen and Curetis, comply with the complexities of a global business, achieve the synergies we expect, successfully implement the combined company’s strategic and business goals and objectives, and advance our current and planned 510(k) clearance submissions with the FDA, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
No Offer or Solicitation
This press release is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information and Where to Find It
In connection with the transactions contemplated by the Implementation Agreement (the definitive agreement related to the proposed business combination between the Company and Curetis GmbH), a Registration Statement on Form S-4 (File No. 333-234657) has been filed with and declared effective by the Securities and Exchange Commission (the “SEC”). Investors and security holders are encouraged to read the registration statement and any other relevant documents filed with the SEC, including the proxy statement/prospectus that forms a part of the registration statement. Such documents contain important information about the proposed transaction. The definitive proxy statement/prospectus was first mailed to stockholders of the Company on or about January 27, 2020. This communication is not a substitute for the registration statement, the proxy statement/prospectus or any other document that OpGen may send to its stockholders in connection with the proposed transaction. Investors and security holders will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov, or from the Company at its website, www.opgen.com.
OpGen Contact:
Michael Farmer
Vice President, Marketing
(240) 813-1284
[email protected]
[email protected]
Press Contact:
Matthew Bretzius
FischTank Marketing and PR
[email protected]
Investor Contacts:
Joe Green
Edison Group
[email protected]
Artificial Intelligence
HER HIGHNESS SHEIKHA MOZA FORMALLY LAUNCHES QATAR PRECISION HEALTH INSTITUTE
Institute builds on 10 years of genomics research to address the under-representation of the Arab genome and unravel a more representative map of the human race
DOHA, Qatar, May 1, 2024 /PRNewswire/ — Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, officially launched the Qatar Precision Health Institute, a national body aimed at leveraging the country’s advanced genomics research to accelerate personalized healthcare – leading to more precise treatments and improved health outcomes for people in the Arab world and beyond.
The Qatar Precision Health Institute builds on the groundbreaking work of Qatar Biobank and Qatar Genome Programme, uniting the efforts of Qatar Foundation’s research institutes to provide insights that reveal the effects of lifestyle, environment, and genetics on the Arab population.
Her Highness, Sheikha Moza bint Nasser, spoke at the formal launch event, emphasizing the importance of raising public awareness on the benefits of precision health. She said:
“I am proud that Qatar was the first country in the region to establish a population-based genome program, and has played a pioneering role in ensuring that Arab genomes are included in global genomic databases. Qatar’s efforts have led to faster and more accurate diagnoses of multiple diseases for people from the region. QPHI is building on those successes and taking our knowledge forward to implement clinical solutions that will lead to a healthier future not only for our citizens but for people around the world.”
Qatar Foundation’s work in the field of precision health led to the creation of the Qatari genome catalog, comprising more than 88 million variants, 24 million of which had never been reported previously in international databases.
Dr. Said Ismail, Acting President of QPHI, said:
“The Middle East is home to more than 400 million people, and is one of the world’s oldest inhabited regions, yet it is the most underrepresented in genome sequencing, as over 95% of available genome data comes from Western Europe and North America. Through research and clinical trials conducted at QPHI, we aim to improve the representation of Arab genomes in these datasets, empowering scientists to unravel the complete map of genomes that define the allelic spectrum of the human race, including Africa, East and Southeast Asia.”
QPHI will advance the study of the Arab genome through recruiting Qataris and long-time residents in large numbers, analyzing their biological samples, as well as information about their health and lifestyle. In doing so, it will make vital data accessible for researchers across the region and the world. Partnerships with leading global genomics institutes, including The Global Alliance for Genomics and Health, as well as the Health Institutes of Turkey will ensuring the transferability of discoveries, and strengthen genomics research on a global scale.
To date, Qatar Genome Programme has sequenced the genomes of over 40,000 Qataris or long-term Qatar residents, generating a wealth of data that has helped to inform diagnoses and treatments that have saved lives.
Through the use of precision medicine, a great number of diseases can be detected early, or avoided altogether. Interventions such as rapid genetic screening for heart patients has led to targeted treatment and a reduction in the number of days patients need to stay in hospital, while mandatory newborn screening through heel prick tests screens for over 80 disorders, giving doctors and parents the ability to detect treatable diseases before clinical presentation.
By seamlessly integrating cutting-edge research with clinical applications, QPHI will equip healthcare providers with the means to provide personalized treatment and elevate the standard of care while cementing Qatar’s position as a frontrunner in precision medicine on the global stage.
For more about Qatar Foundation, please visit qf.org.qa.
For more about QPHI, please visit qphi.org.qa
Photo: https://mma.prnewswire.com/media/2401712/Qatar_Foundation.jpg
View original content:https://www.prnewswire.co.uk/news-releases/her-highness-sheikha-moza-formally-launches-qatar-precision-health-institute-302132869.html
Artificial Intelligence
ION LookOut named “Most Innovative Trade Surveillance Solution” at A-Team Innovation Awards 2024
LONDON, May 1, 2024 /PRNewswire/ — ION, a global leader in trading and workflow automation software, high-value analytics and insights, and strategic consulting to financial institutions, central banks, governments, and corporates, announces that ION LookOut has been named “Most Innovative Trade Surveillance Solution” at the A-Team Innovation Awards 2024.
The A-Team Innovation Awards recognize innovative projects and teams across the vendor and practitioner communities that leverage new and emerging technologies to deliver cutting-edge solutions for financial institutions in capital markets. The awards focus on data management, trading technology, ESG, and regtech suppliers whose contributions are advancing these areas.
ION LookOut, developed by LIST – an ION company, is a multi-asset trade surveillance solution used across multiple jurisdictions. Machine Learning for Alarm Classification (MLAC), ION LookOut’s AI-based assistant, helps compliance teams classify multiple alerts, reducing time and effort, and improving efficiency. MLAC optimizes alert management by learning from the past behavior of compliance officers. It helps reduce the workload of compliance officers while raising alarms for the necessary level of tracking activity. The automatic closure of low-profile alerts further streamlines the process, saving time.
“We are thrilled with ION LookOut’s win at the A-Team Innovation Awards 2024. The recognition reflects ION’s dedication to delivering high-value solutions that address our customers’ evolving needs,” said Alvise Insalaco, Chief Executive Officer: LIST.
“It’s an honor to have ION LookOut recognized for its innovative trade surveillance solution,” said Mirko Marcadella, Chief Product and Marketing Officer: LIST. “This award is a testament to ION’s unwavering commitment to push the boundaries of innovation and deliver solutions that empower our customers.”
Angela Wilbraham, CEO at A-Team Group and 4th annual A-Team Innovation Awards 2024 host, commented, “Many congratulations to ION for winning the Most Innovative Trade Surveillance Solution award in recognition of their achievement in delivering high levels of innovation to financial institutions. They should be deservedly proud of this accomplishment.”
ION LookOut was also named Best Solution for Record Retention at the RegTech Insight Awards APAC 2024 earlier this year, further demonstrating ION’s consistent track record of delivering award-winning products.
About ION
ION provides mission-critical trading and workflow automation software, high-value analytics and insights, and strategic consulting to financial institutions, central banks, governments, and corporates. Our solutions and services simplify complex processes, boost efficiency, and enable better decision-making. We build long-term partnerships with our clients, helping transform their businesses for sustained success through continuous innovation. For more information, visit https://iongroup.com/
About ION Markets
ION Markets provides transformative technology and solutions to financial institutions dealing in asset management, cleared derivatives, equities, fixed income, foreign exchange, and secured funding. Our award-winning end-to-end solutions simplify clients’ operations by automating the full trade lifecycle, providing tools to manage risk, and maximizing access to liquidity, while giving real-time access to critical information required for timely operational decisions and execution on a global scale. For more information, visit https://iongroup.com/markets/
About LIST
An ION company, LIST is a leading financial technology provider to the global trading community, including trading venues, market makers, brokers, asset managers, risk managers, and compliance officers. LIST’s innovative turnkey products and delivery, driven by customers’ needs, play a key role in supporting successful business growth in today’s volatile times. Continuous innovation and client partnerships around the globe have built trust and reliance on LIST’sunique real-time and data analytics capabilities. For more information, visit https://www.list-group.com/.
About A-Team Innovation Awards 2024
The A-Team Innovation Awards celebrate innovative projects and teams across the vendor and practitioner communities that make use of new and emerging technologies to deliver high-value solutions for financial institutions in capital markets, with a specific focus on data management, trading technology, ESG and regtech suppliers. For more information, visit https://a-teaminsight.com/awards/a-team-innovation-awards/
All product and company names herein may be trademarks of their registered owners.
View original content:https://www.prnewswire.co.uk/news-releases/ion-lookout-named-most-innovative-trade-surveillance-solution-at-a-team-innovation-awards-2024-302131767.html
Artificial Intelligence
Open ECX announces partnership with Medius to offer enhanced AP automation capabilities
MANCHESTER, England, May 1, 2024 /PRNewswire/ — Following its recent launch into the channel market, leading e-trading solutions and Accounts Payable (AP) automation software provider, Open ECX, has announced a new partnership with Medius to provide their enhanced suite of advanced AP automation solutions. Open ECX’s statement reconciliation functionality together with Medius’s AP automation and fraud detection offerings offer organisations the ability to automate time consuming, error prone manual processes.
The collaboration will see Open ECX’s statement reconciliation functionality providing a true end to end automation for businesses looking to enhance their Accounts Payable (AP) automation and compliance levels.
Matt Rhodus, VP of Business Development & Strategic Initiatives at Medius, commented: “The partnership with Open ECX fills a void in our product offering with a statement matching and reconciliation solution that integrates with Medius’s AP automation platform. The expertise that the Open ECX team has in industries like construction means that customers get even more operational efficiencies in their financial operations.”
Open ECX is a leading provider of integrated business solutions, including e-trading, statement reconciliation and AP automation, and a pioneer in the P2P space. Its suite of products are designed to enhance operational efficiency and streamline AP processes through seamless integration, automation and innovative technologies, and are compatible with most finance systems used across a multitude of industries and use cases.
Charles Robinson, CCO, Open ECX commented: “At a time when businesses are demanding much more from their finance automation solutions, we’re delighted to be partnering with Medius. Our evolving suite of products have been designed to help finance leaders automate all transactions, while integrating seamlessly into their existing systems and processes. When combined with the power of Medius’ solutions, the partnership will add huge value to customers who are looking to take advantage of holistic, automated AP systems.”
For press information, interviews and images please contact the Open ECX press office:Sara Donnelly: [email protected] T: 07495 090385Clare Wall: [email protected] T: 07974 161127
For more information visit: www.openecx.com
For more information from Medius, please contact:Francesca Cahill (EMEA) at Fight or Flight, [email protected] / [email protected] +44 330 133 0985
For more information visit: www.medius.com
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/medius/r/open-ecx-announces-partnership-with-medius-to-offer-enhanced-ap-automation-capabilities,c3971365
View original content:https://www.prnewswire.co.uk/news-releases/open-ecx-announces-partnership-with-medius-to-offer-enhanced-ap-automation-capabilities-302132854.html
-
Uncategorized6 days ago
Cherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence5 days ago
Hikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days ago
HITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence5 days ago
Web O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Artificial Intelligence5 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence4 days ago
Cognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Uncategorized5 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry